|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-27
|
|
pubmed:abstractText |
Paclitaxel is an active agent in extensive-stage (ES) small cell lung cancer (SCLC). Nevertheless, the optimal schedule is uncertain. A dose-dense schedule was previously evaluated in a Cancer and Leukemia Group B study of patients with non-SCLC, resulting in a 42% response rate and median survival of 12.3 months. Because of these promising results, this dose and schedule of paclitaxel was evaluated in patients with ES-SCLC.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA114558-02,
http://linkedlifedata.com/resource/pubmed/grant/CA12046,
http://linkedlifedata.com/resource/pubmed/grant/CA16450,
http://linkedlifedata.com/resource/pubmed/grant/CA21060,
http://linkedlifedata.com/resource/pubmed/grant/CA31946,
http://linkedlifedata.com/resource/pubmed/grant/CA33601,
http://linkedlifedata.com/resource/pubmed/grant/CA35113,
http://linkedlifedata.com/resource/pubmed/grant/CA41287,
http://linkedlifedata.com/resource/pubmed/grant/CA45418,
http://linkedlifedata.com/resource/pubmed/grant/CA45808,
http://linkedlifedata.com/resource/pubmed/grant/CA47555,
http://linkedlifedata.com/resource/pubmed/grant/CA47559,
http://linkedlifedata.com/resource/pubmed/grant/CA77440,
http://linkedlifedata.com/resource/pubmed/grant/CA77651
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
158-62
|
|
pubmed:dateRevised |
2008-5-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18303437-Adult,
pubmed-meshheading:18303437-Aged,
pubmed-meshheading:18303437-Aged, 80 and over,
pubmed-meshheading:18303437-Carcinoma, Small Cell,
pubmed-meshheading:18303437-Dose-Response Relationship, Drug,
pubmed-meshheading:18303437-Drug Administration Schedule,
pubmed-meshheading:18303437-Drug Toxicity,
pubmed-meshheading:18303437-Female,
pubmed-meshheading:18303437-Humans,
pubmed-meshheading:18303437-Infusions, Intravenous,
pubmed-meshheading:18303437-Lung Neoplasms,
pubmed-meshheading:18303437-Male,
pubmed-meshheading:18303437-Paclitaxel,
pubmed-meshheading:18303437-Survival Analysis
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
|
|
pubmed:affiliation |
State University of New York Upstate Medical University, Syracuse, New York 13210, USA. grazians@upstate.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
